Synergistic Effect of Celecoxib on 5-fluorouracil-induced Apoptosis in Hepatocellular Carcinoma Patients

Annals of Hepatology

Volumn 9, Issue 4, 2010, Pages 410-418

  Bassiouny, Ahmad R ^a   Zaky, Amira ^a   Neenaa, Hashem M ^b  

^a Alexandria University Faculty Of Science   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Hepatocarcinoma. Celecoxib. 5 flourouracil. Apoptosis

Indexed keywords

ALPHA FETOPROTEIN; BASIC FIBROBLAST GROWTH FACTOR; CASPASE 3; CELECOXIB; CYCLOPHOSPHAMIDE; FLUOROURACIL; GLYCOPROTEIN P; GLYPICAN 3; VASCULOTROPIN; ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYCLOOXYGENASE 2 INHIBITOR; GLYPICAN; PYRAZOLE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; DRUG COMBINATION; DRUG EFFECT; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CYCLOOXYGENASE 2 INHIBITORS; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOROURACIL; GLYPICANS; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; P-GLYCOPROTEIN; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952278548     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31617-5     Document Type: Article

References (34)

1. Cui J, Liu Y, Zhou H, Kang X, Huang C, He YF, Tang Z, et al. Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis. World J Gastroenterol 2008; 14: 1257-62.
2. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-9.
3. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001; 48: 558-64.
4. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serologi-cal marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-23.
5. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000; 113: 355-63.
6. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis; Prog Exp Tum Res Basel Karger 2003; 37: 179-92.
7. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
8. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 2000; 79: 1-38.
9. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxy-genase-2 (COX-2)- Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. JNCI J Natl Cancer Inst 2006; 98: 736-47.
10. Galy B, Creancier L, Prado-Lourenco L, Prats AC, Prats H. p53 directs conformational change and translation inhibition blockade of human fibroblast growth factor 2 mRNA. Oncogenes 2001; 20: 4613-20.
11. Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, Yang PC. Aberrant p53 expression correlates with expression of vascular en-dothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 2002; 20: 900-10.
12. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombos-pondin-1. Science 1994; 265: 1582-84.
13. Andrew J, Henry R. The Anticancer Properties of Selective COX-2 Inhibitors. New Directions for Prevention and Treatment. Cancer prevention program, Columbia Weill Cornell Cancer Centers, New York: 2003. Issue 2.
14. Fantappiè O, Solazzo M, Lasagna N, Platini F, Luciana Tes-sitore L, Mazzanti R. P-Glycoprotein Mediates Celecoxib-Induced Apoptosis in Multiple Drug-Resistant Cell Lines. Cancer Research 2007; 67: 4915-23.
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
17. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study. Ann Surg 2001; 233: 227-35.
18. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellu-lar carcinoma. Cancer Res 2003; 63: 3121-26.
19. Xia W, Zhao T, Lv J, Xu S, Shi J, Wang S, Han X, et al. Cele-coxib enhanced the sensitivity of cancer cells to antican-cer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J Cell Biochem 2009; 108: 181-94.
20. Fantappiè O, Masini E, Sardi I, et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 2002; 35: 843-52.
21. Mazzanti R, Fantappiè O, Fabrizio P, Relli P. Susceptibility to lipid peroxidation of human hepatocellular carcinoma cell lines with different levels of multiple drug-resistant phenotype. Lab Invest 1995; 73: 419-23.
22. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein-im-plications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5: 457-68.
23. Yin F, Shi YQ, Zhao WP, Xiao B, Miao JY, Fan DM. Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas. World J Gastroenterol 2000; 6: 664-70.
24. Kojima H, Endo K, Moriyama H, et al. Abrogation of mito-chondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem 1998; 50(273): 16647-50.
25. Hashitani S, Urade M, Nishimura N, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 2003; 23: 665-72.
26. Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q, Curley SA. Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 2002; 95: 1696-1705.
27. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO. Evaluation of nuclear factor-kappaB, urokinase-type plasmi-nogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 4140-49.
28. Arsura M, Cavin LG. Nuclear factor-kappaB and liver car-cinogenesis. Cancer Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002; 277: 38915-20.
29. Williams CS, Tsujii M, Reese J, Dey SK, Dubois RN. Host Cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-94.
30. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, et al. Phase II Trial of the Combination of Bevaci-zumab and Erlotinib in Patients Lett 2005; 229: 157-69.
31. Who Have Advanced Hepatocellular Carcinoma. J Clin Oncol 2009; 27: 3263.
32. Braicu C, Burz C, Berindan-Neagoe I, Balacescu O, Florin Graur F, Cristea V, Irimie A. Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers 2009; 2: 191-99.
33. Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterology and Hepatology 2010; 25: 129-137.
34. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, Vali S, Reddanna P. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother & Pharmacol 2010; 65: 903-11.